CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness

FDA issued a CRL for Capricor Therapeutics' Deramiocel, citing insufficient evidence of effectiveness and clinical deficiencies, despite HOPE-2 and HOPE-3 meeting primary endpoints. The company is reviewing the letter and has funds for at least 12 months of operations, according to the company.

Original reporting
Published Nov 21, 2026, 10:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness — source image
Decision brief

The 30-second read

$CAPRBearishHigh
01

Why it matters

The regulatory denial is a material negative catalyst, likely triggering a sell‑off and increasing volatility.

02

Market read

The CRL is a fresh, material regulatory event for CAPR, creating immediate trading relevance.

03

What to watch

Potential for partnership or licensing of Deramiocel data to larger pharma could mitigate downside.

Relevance 8/10Novelty 9/10Timing: today

Background

Capricor Therapeutics announced a resubmission of its Deramiocel BLA; the FDA's CRL cites insufficient efficacy despite positive trial endpoints.

Company-level read

Ticker impact

$CAPRBearishHigh confidence
Context

FDA issued a complete response letter rejecting Capricor Therapeutics' resubmitted Deramiocel BLA due to insufficient efficacy evidence.

Expected impact

downward pressure as investors price in the regulatory setback

Evidence & confidence

Regulatory denials for biotech drugs typically trigger sharp sell‑offs; no mitigating data were provided.

Market effects

Biotech sector may see broader risk‑off pressure on other companies awaiting FDA decisions.

U.S. biotech stocks could experience modest declines in Nasdaq‑listed peer group.

Limited to investors focused on U.S. biotech pipelines; minimal global macro effect.

Counterpoint

If Capricor can address FDA concerns quickly, the stock may rebound on a future resubmission.

Key entities

  • Capricor Therapeutics, Inc.

    Biotech firm developing Deramiocel for cardiac repair.

  • U.S. Food and Drug Administration

    Issued the complete response letter rejecting the BLA.

Related articles

$CAPRHigh

Why is Capricor Therapeutics stock surging today?

Capricor Therapeutics (CAPR) stock rose 10% pre-market ahead of the FDA's November 22, 2026 decision on deramiocel, a therapy for Duchenne muscular dystrophy. Analysts JonesTrading and Oppenheimer upgraded CAPR, citing potential approval and peak sales of $2.3B. Despite market downturns, CAPR's surge is driven by FDA anticipation and clinical data.